Publications

Publications 2012

VOLUMETRIC AND MGMT PARAMETERS IN GLIOBLASTOMA PATIENTS: SURVIVAL ANALYSIS

G. Iliadis, V. Kotoula, A.Chatzisotiriou, D. Televantou, A.G. Eleftheraki, S. Lambaki, D. Misailidou, P. Selviaridis, G. Fountzilas

BMC Cancer 2012 Jan 3;12:3


POSTOPERATIVE DOSE-DENSE SEQUENTIAL VERSUS CONCOMITANT ADMINISTRATION OF EPIRUBICIN AND PACLITAXEL IN PATIENTS WITH NODE-POSITIVE BREAST CANCER: 5-YEAR RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP. HE 10/00 PHASE III TRIAL

H. Gogas, U. Dafni, M. Karina, C. Papadimitriou, A. Batistatou, M. Bobos, H.P Kalofonos, A.G Eleftheraki, E. Timotheadou, D. Bafaloukos, C. Christodoulou, C. Markopoulos, E. Briasoulis, P. Papakostas, E. Samantas, P. Kosmidis, G.P Stathopoulos, C. Karanikiotis, D. Pectasides, M.A Dimopoulos, G. Fountzilas

Breast Cancer Research and Treatment 2012 Apr;132(2):609-19


PROGNOSTIC SIGNIFICANCE OF UBE2C MRNA EXPRESSION IN HIGH-RISK EARLY BREAST CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

A. Psyrri, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, A. Batistatou, E. Bournakis, E. Timotheadou, H. Gogas, G. Aravantinos, C. Christodoulou, T. Makatsoris, H. Linardou, D. Pectasides, N. Pavlidis, T. Economopoulos, G. Fountzilas

Annals of Oncology 2012 Jan 16


EXPRESSION OF ANGIOGENIC MARKERS IN THE PERIPHERAL BLOOD OF DOCETAXEL-TREATED ADVANCED BREAST CANCER PATIENTS. A HELLENIC ONCOLOGY GROUP (HECOG) STUDY

D. Pectasides, G. Papaxoinis, V. Kotoula, H. Fountzilas, I. Korantzis, A. Koutras, A.M. Dimopoulos, P. Papakostas, G. Aravantinos, I. Varthalitis, P. Kosmidis, D. Skarlos, E. Bournakis, D. Bafaloukos, H.P. Kalofonos, K.T. Kalogeras, G. Fountzilas

Oncology Reports 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504


 HER2 AND TOP2A IN HIGH-RISK EARLY BREAST CANCER PATIENTS TREATED WITH ADJUVANT EPIRUBICIN-BASED DOSE-DENSE SEQUENTIAL CHEMOTHERAPY
G. Fountzilas, Ch. Valavanis, V. Kotoula, A.G. Eleftheraki, K.T. Kalogeras, O. Tzaida, A. Batistatou, R. Kronenwett, R.M. Wirtz, M. Bobos, E. Timotheadou, N. Soupos, G. Pentheroudakis, H. Gogas, D. Vlachodimitropoulos, G. Polychronidou, G. Aravantinos, A. Koutras, Ch. Christodoulou, D. Pectasides and P.Arapantoni
J Trans Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10


IDENTIFICATION AND VALIDATION OF GENE EXPRESSION MODELS THAT PREDICT CLINICAL OUTCOME IN PATIENTS WITH EARLY-STAGE LARYNGEAL CANCER
E. Fountzilas, K. Markou, K. Vlachtsis, A. Nikolaou, P. Arapantoni-Dadioti, E. Ntoula, G. Tassopoulos, M. Bobos, P. Konstatninopoulos, G. Fountzilas & D. Spentzos
Ann Oncol.2012 Aug;23(8):2146-53. doi: 10.1093/annonc/mdr576 (Epub 2012 Jan 4)


VINORELBINE VERSUS PACLITAXEL FOR PATIENTS WITH ADVANCED NON–SMALL CELL LUNG CANCER (NSCLC) AND A PERFORMANCE STATUS OF 2
P.A. Kosmidis, K. Syrigos, H.P. Kalofonos, M.A Dimopoulos, D. Skarlos, N. Pavlidis, I. Boukovinas, D. Bafaloukos, D. Pectasides, Ch. Bacoyiannis and G. Fountzilas
Anticancer Res. 2012 Jan;32(1):175-81


PROGNOSTIC UTILITY OF ANGIOGENESIS AND HYPOXIA EFFECTORS IN PATIENTS WITH OPERABLE SQUAMOUS CELL CANCER OF THE LARYNX
G. Pentheroudakis, I. Nicolaou, V. Kotoula, H. Fountzilas, K. Markou, A.G. Eleftheraki, A. Fragkoulidi, I. Karasmanis, A. Tsigka, N. Angouridakis, K. Vlachtsis, A. Nikolaou, N. Pavlidis, G. Fountzilas
Oral Oncol. 2012 Aug;48(8):709-16. doi: 10.1016/j.oraloncology.2012.02.002 (Epub 2012 Feb 25)


THE PROGNOSTIC AND PREDICTIVE VALUE OF MRNA EXPRESSION OF VEGF FAMILY MEMBERS IN BREAST CANCER: A STUDY IN PRIMARY TUMORS OF HIGH-RISK EARLY BREAST CANCER PATIENTS PARTICIPATING IN A RANDOMIZED HELLENIC COOPERATIVE ONCOLOGY GROUP TRIAL
H. Linardou, , K.T. Kalogeras, R. Kronenwett, G. Kouvatseas, R.M. Wirtz, F. Zagouri, H. Gogas, Ch. Christodoulou, A.K. Koutras, E. Samantas, D. Pectasides, D. Bafaloukos, G. Fountzilas
Breast Cancer Res. 2012 Nov 12;14(6):R145


DIFFERENTIAL RESPONSE OF IMMUNOHISTOCHEMICALLY DEFINED BREAST CANCER SUBTYPES TO DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY
G. Fountzilas, U. Dafni, M. Bobos, A. Batistatou, V. Kotoula, H. Trihia, V. Malamou-Mitsi, S. Miliaras, S. Chrisafi, S. Papadopoulos, M. Sotiropoulou, Th. Fillipidis, H. Gogas, T. Koletsa, D. Bafaloukos, D. Televantou, K.T. Kalogeras, D. Pectasides, D.V. Skarlos, A. Koutras, M.A. Dimopoulos
PloS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946 (Epub 2012 Jun 5)


IMPROVED OUTCOME OF HIGH-RISK EARLY HER2-POSITIVE BREAST CANCER WITH HIGH CXCL13/CXCR5 MRNA EXPRESSION
E. Razis, K.T. Kalogeras, V. Kotoula, A.G. Eleftheraki, N. Nikitas, R. Kronenwett, E. Timotheadou, Ch. Christodoulou, D. Pectasides, H. Gogas, R.M. Wirtz, Th.Makatsoris, Di. Bafaloukos, G. Aravantinos, D. Televantou, N. Pavlidis, G. Fountzilas
Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006


IMMUNOHISTOCHEMICAL STUDY OF THE EPITHELIAL MESENCHYMAL TRANSITION PHENOTYPE IN CANCER OF UNKNOWN PRIMARY: INCIDENCE, CORRELATIONS AND PROGNOSTIC UTILITY
A. Stoyianni, A. Goussia, G. Pentheroudakis, V.Siozopoulou, E. Ioachim, D. Krikelis, V. Golfinopoulos, A. Cervantes, M. Bobos, Th. Fotsis, S. Bellou, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis
Anticancer Res. 2012 Apr;32(4):1273-81


INTRACELLULAR SIGNALLING VIA THE AKT AXIS AND DOWNSTREAM EFFECTORS IS ACTIVE AND PROGNOSTICALLY SIGNIFICANT IN CARCINOMAS OF UNKNOWN PRIMARY (CUP): A STUDY OF 100 CUP CASES
V. Golfinopoulos, G. Pentheroudakis, A. Goussia, V. Siozopoulou, M. Bobos, D. Krikelis, A. Cervantes, T. Ciuleanu, M. Marsellos, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis
Ann Oncol. 2012 Oct;23(10):2725-30 (Epub 2012 May 6)


PROFILING IMMUNOHISTOCHEMICAL EXPRESSION OF NOTCH1-3, JAGGED1, CMET, PHOSPHO-MAPK IN 100 CARCINOMAS OF UNKNOWN PRIMARY
D. Krikelis, G. Pentheroudakis, A.Goussia, V.Siozopoulou, M. Bobos, D. Petrakis, A. Stoyianni, V. Golfinopoulos, A. Cervantes, T. Ciuleanu, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis
Clin Exp Metastasis. 2012 Aug;29(6):603-14. doi: 10.1007/s10585-012-9474-4 (Epub 2012 Apr 19)


INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY AND WEEKLY CISPLATIN VERSUS THE SAME CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA: A RANDOMIZED PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) WITH BIOMARKER EVALUATION
G. Fountzilas, E. Ciuleanu, M. Bobos, A. Kalogera-Fountzila, A.G. Eleftheraki, G. Karayannopoulou, T. Zaramboukas, A. Nikolaou, K. Markou, L. Resiga, D. Dionysopoulos, E. Samantas, H. Athanassiou, D. Misailidou, D. Skarlos, T. Ciuleanu
Ann Oncol. 2012 Feb;23(2):427-35. doi: 10.1093/annonc/mdr116 (Epub 2011 Apr 27)


TRIPLE-NEGATIVE PHENOTYPE IS OF ADVERSE PROGNOSTIC VALUE IN PATIENTS TREATED WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY: A TRANSLATIONAL RESEARCH ANALYSIS IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) RANDOMIZED PHASE III TRIAL
P. Skarlos, C. Christodoulou, K.T. Kalogeras, A.G. Eleftheraki, M. Bobos, A. Batistatou, C. Valavanis, O. Tzaida, E. Timotheadou, R. Kronenwett, R.M Wirtz, I. Kostopoulos, D. Televantou, E. Koutselini, I. Papaspirou, C.A Papadimitriou, D. Pectasides, H. Gogas, G. Aravantinos, N. Pavlidis, P. Arapantoni, D.V. Skarlos, G. Fountzilas
Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9 (Epub 2011 Sep 8)


XELΙRI-BEVACIZUMAB VERSUS FOLFIRI-BEVACIZUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE III TRIAL WITH COLLATERAL BIOMARKER ANALYSIS
D. Pectasides, G. Papaxoinis, K.T. Kalogeras, A.G. Eleftheraki, I. Xanthakis, Th. Makatsoris, E. Samantas, I. Varthalitis, P. Papakostas, N. Nikitas, C.N. Papandreou, G. Pentheroudakis, E. Timotheadou, A. Koutras, J. Sgouros, D. Bafaloukos, G. Klouvas, Th. Economopoulos, K.N. Syrigos, G. Fountzilas
BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271


TOPOISOMERASE II alpha GENE AMPLIFICATION IS A FAVORABLE PROGNOSTIC FACTOR IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB
G. Fountzilas, Ch. Christodoulou, M. Bobos, V. Kotoula, A.G. Eleftheraki, I. Xanthakis, A. Batistatou, G. Pentheroudakis, N. Xiros, I. Papaspirou, A. Koumarianou, P. Papakostas, D. Bafaloukos, D.V. Skarlos, K.T. Kalogeras
J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212


PREVALENCE OF BRCA1 MUTATIONS AMONG 403 WOMEN WITH TRIPLE-NEGATIVE BREAST CANCER: IMPLICATIONS FOR GENETIC SCREENING SELECTION CRITERIA: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
F. Fostira, M. Tsitlaidou, C. Papadimitriou, M. Pertesi, E. Timotheadou, A.V. Stavropoulou, S. Glentis, E. Bournakis, M. Bobos, D. Pectasides, P. Papakostas, G. Pentheroudakis, H. Gogas, P. Skarlos, E. Samantas, D. Bafaloukos, P.A. Kosmidis, A. Koutras, D. Yannoukakos, I. Konstantopoulou, G. Fountzilas
Breast Cancer Res. Treat. 2012 Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9 (Epub 2012 Mar 21)


PROGNOSTIC SIGNIFICANCE OF RACGAP1 MRNA EXPRESSION IN HIGH-RISK EARLY BREAST CANCER.A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY
K. Pliarchopoulou, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, A.G. Eleftheraki, A. Batistatou, M. Bobos, N. Soupos, G. Polychronidou, H. Gogas, E. Samantas, C. Christodoulou, T. Makatsoris, N. Pavlidis, D. Pectasides, G. Fountzilas
Cancer Chemother Pharmacol. 2012 Oct 25. [Epub ahead of print]


LAPATINIB AND CAPECITABINE COMBINATION FOR HER2 POSITIVE METASTATIC BREAST CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
H. Linardou, D.V. Skarlos, C. Christodoulou, A. Koutras, D. Bafaloukos, P. Papakostas, E. Kostouras, I. Grossi, E. Galani, D. Pectasides, G. Fountzilas
Mediterranean Oncology Journal (MOJ). 2012;1:40-44


COMBINATION TREATMENT WITH METRONOMIC TEMOZOLOMIDE, BEVACIZUMAB AND LONG-ACTING OCTREOTIDE FOR MALIGNANT NEUROENDOCRINE TUMOURS
A. Koumarianou, S. Antoniou, G. Kanakis, N. Economopoulos, D. Rontogianni, A. Ntavatzikos, N. Tsavaris, D. Pectasides, G. Dimitriadis, G. Kaltsas
Endocr Relat Cancer. 2012 Jan 9;19(1):L1-4. doi: 10.1530/ERC-11-0287. Print 2012 Feb


EXPRESSION OF DNA REPAIR AND REPLICATION GENES IN NON-SMALL CELL LUNG CANCER (NSCLC): A ROLE FOR THYMIDYLATE SYNTHETASE (TYMS)
V. Kotoula, D. Krikelis, V. Karavasilis, T. Koletsa, A.G. Eleftheraki, D. Televantou, Ch. Christodoulou, S. Dimoudis, I. Korantzis, D. Pectasides, K.N. Syrigos, P. A Kosmidis, G. Fountzilas
BMC Cancer. 2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342


MOLECULAR PREDICTORS OF RESPONSE TO TYROSINE KINASE INHIBITORS IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER
S. Murray, V. Karavasilis, M. Bobos, E. Razis, S. Papadopoulos, Ch. Christodoulou, P. Kosmidis, G. Fountzilas
J Exp Clin Cancer Res. 2012 Sep 19;31(1):77. doi: 10.1186/1756-9966-31-77


COST-MINIMIZATION ANALYSIS OF THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER IN GREECE
V. Fragoulakis, V. Papagiannopoulou, G. Kourlaba, N. Maniadakis and G. Fountzilas
Clin Ther. 2012 Oct;34(10):2132-42. doi: 10.1016/j.clinthera.2012.09.005


ASSOCIATION OF ERCC1SNPs WITH OUTCOME IN PLATINUM-TREATED PATIENTS WITH ADVANCED UROTHELIAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
N. Nikitas, A. Karadimou, E. Tsitoura, N. Soupos, M. Tsiatas, V. Karavasilis, D. Pectasides, N. Pavlidis, M. Chrisofos, I. Adamakis, S. Murray, G. Fountzilas, M.A. Dimopoulos, A. Bamias
Pharmacogenomics. 2012 Nov;13(14):1595-607. doi: 10.2217/pgs.12.162


PROSPECTIVE, OPEN-LABEL, RANDOMIZED, PHASE III STUDY OF TWO DOSE-DENSE REGIMENS MVAC VERSUS GEMCITABINE/CISPLATIN IN PATIENTS WITH INOPERABLE, METASTATIC OR RELAPSED UROTHELIAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY (HE1603)
A. Bamias, U. Dafni, A. Karadimou, E. Timotheadou, G. Aravantinos, A. Psyrri, I. Xanthakis, M. Tsiatas, M. Koutoulidis, C. Constantinidis, C. Hatzimouratidis, E. Samantas, A. Visvikis, M. Chrisophos, K. Stravodimos, C. Deliveliotis, A. Eleftheraki, D. Pectasides, G. Fountzilas, M.A. Dimopoulos
Ann Oncol. 2012 Nov 7. [Epub ahead of print]


SURVIVAL FROM BREAST CANCER IN RELATION TO ACCESS TO TERTIARY HEALTHCARE, BODY MASS INDEX, TUMOR CHARACTERISTICS AND TREATMENT: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY
P. Panagopoulou, H. Gogas, N. Dessypris, N. Maniadakis, G. Fountzilas, E.T. Petridou
Eur J Epidemiol. 2012 Nov;27(11):857-66. doi: 10.1007/s10654-012-9737-z (Epub 2012 Oct 20)


GLOBAL MICRORNA PROFILING IN FAVORABLE PROGNOSIS SUBGROUPS OF CANCER OF UNKNOWN PRIMARY (CUP) DEMONSTRATES NO SIGNIFICANT EXPRESSION DIFFERENCES WITH METASTASES OF MATCHED KNOWN PRIMARY TUMORS
G. Pentheroudakis, Y. Spector, D. Krikelis, V. Kotoula, E. Meiri, V. Malamou-Mitsi, G. Fountzilas, M. Sanden, N. Pavlidis, H. Benjamin, R. Aharonov
Clin Exp Metastasis. 2012 Nov 4. [Epub ahead of print]


DARPP32, STAT5 AND STAT3 MRNA EXPRESSION RATIOS IN GLIOBLASTOMAS ARE ASSOCIATED WITH PATIENT OUTCOME
D. Televantou, G. Karkavelas, P. Hytiroglou, S. Lampaki, G. Iliadis, P. Selviaridis, K.S. Polyzoidis, G. Fountzilas, V. Kotoula
Pathol Oncol Res. 2012 Dec 20. [Epub ahead of print]


SAMPLE PARAMETERS AFFECTING THE CLINICAL RELEVANCE OF RNA BIOMARKERS IN TRANSLATIONAL BREAST CANCER RESEARCH
V. Kotoula, K.T. Kalogeras, G. Kouvatseas, D. Televantou, R. Kronenwett, R.M. Wirtz, G. Fountzilas
Virchows Arch. 2012 Dec 20. [Epub ahead of print]